Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Patients treated with Trikafta or other cystic fibrosis therapies can also still have declining lung function, or may cut ...

Cystic fibrosis has traditionally been considered a fatal disease. But thanks to medical advancements and treatments, many patients now live longer, healthier lives. Patients in Saskatchewan may ...

Patients treated with Trikafta or other cystic fibrosis therapies can also still have declining lung function, or may cut dosing due to side effects. The company intends to pick one of its ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...